- Home
- Equipment
- netherlands
- tumor specificity
Show results for
Refine by
Applications
- Solution for Clinical Trials
- Solution for Access to Investigational Medicines
- Actionable Molecular Diagnostic System for Physicians
- Diagnostic Solutions for Lung Cancer
- Liquid Biopsy Solutions for Breast Cancer
- Diagnostic Solutions for Colorectal Cancer
- Radioactive Drugs for Diagnostics
- Radioactive Drugs for Therapeutics
Tumor Specificity Equipment & Supplies In Netherlands
67 equipment items found
Manufactured by:SurgiMab based inMontpellier, FRANCE
SGM-101, currently in Phase III for the delineation of primary and recurrent tumor and metastases in patients undergoing surgery for colorectal cancer, is a tumor-specific antibody conjugated to a near-infrared fluorochrome. It selectively binds a specific marker overexpressed in gastrointestinal and other ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while simultaneously enhancing immune modulation through the conditional activity of a natural immunomodulatory ...
by:Onegene Biotechnology based inSuwon, SOUTH KOREA
OGB23501 is a first-in-class tri-specific tumor microenvironment (TME) immune activator, which simultaneously targets PD-1, CTLA-4, and VEGF. We aim to develop it as a potential backbone therapy for melanoma, NSCLC, HCC, and renal ...
Manufactured by:Treos Bio Limited based inLondon, UNITED KINGDOM
Off-the-shelf products contain 6-12 shared tumor-specific antigen derived peptides optimized for a population. They are personalized with a candidate companion diagnostic test (CDx). In silico trials predicted that these peptides induce exceptionally broad T cell responses against at least 3 tumor-specific antigens in high ...
Manufactured by:MV BioTherapeutics SA based inBellinzona, SWITZERLAND
MV010/MV004, in cancer immunotherapy • Significant increase of tumor specific cytotoxic T cells infiltrating the tumor microenvironment by combining MV010/MV004 to anti-PD-L1 administration in murine models. • Significantly improved tumor eradication and resistance to subsequent grafting and improved survival in murine models. ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
Azymetric™ is the best-in-class platform for therapeutic antibodies that can simultaneously bind to multiple distinct locations on a target or to multiple targets, resulting in unique mechanisms of action not accessible through typical monospecific antibodies. Azymetric™ bispecific antibodies can block multiple signaling pathways, recruit immune cells to tumors, ...
Manufactured by:Taiho Oncology, Inc. based inPrinceton, NEW JERSEY (USA)
Tumors with specific FGFR aberrations: Solid tumors, Gastric cancer, Myelolymphoid neoplasms PHASE ...
Manufactured by:Scytek Laboratories Inc based inLogan, UTAH (USA)
Isotype: IgG1, kappa, Species Reactivity: Human, Mouse, and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this antibody does not react with CLIP (aa 17-39 of ACTH). Anti-ACTH is a useful marker in classification ...
Manufactured by:Scytek Laboratories Inc based inLogan, UTAH (USA)
Species: Mouse, Immunogen: N-terminal fragment of human ACTH conjugated to KLH,Clone: 57,Isotype: IgG1, kappa, Species Reactivity: Human and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this antibody does not ...
Manufactured by:Scytek Laboratories Inc based inLogan, UTAH (USA)
Species: Mouse,Immunogen: Synthetic peptide corresponding to aa 1-24 of human ACTH, Clone: AH26, Isotype: IgG1, kappa, Species Reactivity: Human, Mouse and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this ...
Manufactured by:Histo-Line Laboratories based inPantigliate (MI), ITALY
Species Reactivity: Human, Mouse, and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this antibody does not react with CLIP (aa 17-39 of ACTH). Anti-ACTH is a useful marker in classification of pituitary ...
Manufactured by:Histo-Line Laboratories based inPantigliate (MI), ITALY
Species Reactivity: Human, Mouse, and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this antibody does not react with CLIP (aa 17-39 of ACTH). Anti-ACTH is a useful marker in classification of pituitary ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
By combining bi-valency with bi-specificity in the tetravalent format, the dual checkpoint molecule utilizes avidity and bi-specificity to improve anti-cancer immune cell function. The specificity enhancement both synergistically enhance and expand the breadth of immune cell activity that is diminished in cancer patients (SEBA). The ...
Manufactured by:Nuclidium AG based inBasel, SWITZERLAND
Nuclidium AG leverages the unique properties of copper radionuclides to advance precision radiotherapy and diagnostics. Their proprietary CuTrace™ platform combines copper nuclides with tumor-specific molecules, creating diagnostic and therapeutic pairs designed to optimize the safety and efficacy profile in cancer treatment. These radionuclides, including ...
by:Metaclipse Therapeutics Corporation based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a patient’s tumor tissue that Metaclipse modifies with a ‘protein ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels ...
by:TheraBionic GmbH based inEttlingen, GERMANY
The TheraBionic P1 produces low levels radiofrequency (RF) electromagnetic fields, which are amplitude-modulated at tumor-specific frequencies. The device is coupled with a spoon-shaped antenna, which is placed in the patient’s mouth, more precisely on the anterior part of the patient’s tongue for three sixty-minute sessions per day. When the ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
BRAF mutations are present in multiple types of cancer, including 40% in melanoma, 9% in colorectal cancer (CRC), and 2% in lung cancer. High levels of BRAF protein expression in these tumors suggest susceptibility to T cells targeting the mutation.3 Previous research has shown a durable complete response through transfer of tumor-infiltrating lymphocytes ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement ...
by:CC Diagnostics based inGroningen, NETHERLANDS
During their fundamental research in the last 15 years, this group has identified and clinically-validated numerous CIN2+-specific tumor-suppressor genes deregulated by DNA hypermethylation. They reported that DNA methylation status of these genes has predictive value whether or not cervical cancer or its precursors are present in cervical scrapings. Therefore, ...